Munise Daye, Selami Aykut Temiz

Hematolojik Parametrelerin Tip 1 ve Tip 2 Psoriasiste Metabolik Sendrom ile İlişkisi

Amaç: Psöriazis kardiyovasküler hastalıklar için bağımsız bir risk faktörü olarak kabul edilmiştir ve metabolik sendromla (MS) yakından ilişkili olduğu bilinmektedir. Ortalama trombosit hacmi (MPV), trombosit dağılım genişliği (PDW), eritrosit dağılım genişliği (RDW) düzeylerinin inflamasyonu öngören parametreler olduğu bilinmektedir. Çalışmalar, bu parametrelerin bazılarının psöriazisi olan hastalarda MS’yi tahmin etmek için kullanılabileceğini saptamıştır. Literatürde tip 1 ve tip 2 psoriazisi ayrı ayrı değerlendirerek MS sıklığı ile hematolojik parametreler arasındaki ilişkiyi gösteren bir çalışma saptanmamıştır. Çalışmamızda, bu hematolojik parametrelerin MS’yi tahmin etmede tip 1 ve tip 2 psöriazis açısından farkını saptamayı amaçladık. Gereç ve Yöntemler: Çalışmaya dermatoloji kliniğine başvuran 18 yaş üstü 93 psoriazis tanılı hasta ile yaş ve cinsiyet benzer 93 kontrol grubu olmak üzere toplam 186 katılımcı dahil edildi. Bulgular: PDW psoriazis ve kontrol grubu arasında anlamlı olarak farklıyken, RDW tip 2 psoriazis grubu ile tip 1 psoriazis grubu arasında anlamlı derecede farklı saptandı. MPV, RDW ve PDW hem tip 1 hem de tip 2 psoriazis grupların MS gruplarında daha yüksek olmasına rağmen istatistiksel olarak anlamlı bir fark saptanmadı. Sonuç: Bu çalışma, tip 1 ve tip 2 psoriazisli hastalarda MS sıklığının ve ilişkili parametrelerinin farklı olduğunu gösterdi ve tip 2 psoriazisin MS ile daha fazla birliktelik gösterdiği saptandı. Ayrıca inflamatuar parametrelerden özellikle RDW’nin tip 2 ve tip 1 psoriazis ve komorbiditeler için önemli bir belirteç olabileceği saptandı.

The Relations Between Hematological Parameters and Metabolic Syndrome in Type 1 and Type 2 Psoriasis

Objective: Psoriasis has been accepted as an independent risk factor for cardiovascular diseases and is known to be closely related to metabolic syndrome (MS). It is known that the mean platelet volume (MPV), the platelet distribution width (PDW), the red blood cell distribution width (RDW) levels are parameters predicting systemic inflammation. Studies have found that some of these parameters can be used to predict MS in patients with psoriasis. In the literature, there is no study showing the relationship between the frequency of MS and hematological parameters by evaluating type 1 and type 2 psoriasis separately. In our study, we aimed to determine the difference of these hematological parameters in predicting MS in terms of type 1 and type 2 psoriasis. Materials and Methods: A total of 186 participants were included in the study, 93 patients over 18 years of age with psoriasis diagnosed and 93 age and gender equivalent control groups, who applied to the dermatology clinic. Results: While PDW was significantly different between the psoriasis and control group, RDW was significantly different in the type 2 psoriasis group compared to the type 1 psoriasis group. Although MPV, RDW, and PDW were higher in the MS groups for both type 1 and type 2 psoriasis groups, and they did not create a statistically significant difference in any of them. Conclusions: This study showed that the frequency of MS and related parameters were different between patients with type 1 and type 2 psoriasis, and we found that type 2 psoriasis was more associated with MS. In addition, we think that among the inflammatory parameters, especially RDW, may be an important marker for type 2 and type 1 psoriasis and comorbidities.

PDF

___

1.Temiz SA, Özer İ, Ataseven A, Dursun R, Uyar M. The effect of smoking on the psoriasis: Is it related to nail involvement?. Dermatol Ther 2020;33:e13960.
2.Delaporte E. Immune-mediated inflammatory diseases and psoriasis. Ann Dermatol Venereol 2008;135:269-74.
3.Daye M, Temiz SA, Isık B. The relationship between lichen planus and metabolic syndrome. J Cosmet Dermatol 2020;20:2635-9.
4.Günaydin A, Aytimur D, Özdemir, F. Psoriasis ve metabolik sendrom/ Psoriasis and metabolic syndrome. Turkderm 2014;48:95-9.
5.Demirbaş A, Kurtipek GS, Tunçez A, Akyürek F, Demirbaş GU. The role of cystatin‐C and fetuin‐A in the determination of early atherosclerotic risk in psoriasis patients. Dermatol Ther 2020;33(6):e13898.
6.Dogan S, Atakan N. Red blood cell distribution width is a reliable marker of inflammation in plaque psoriasis. Acta Dermatovenerol Croat 2017;25:26-31.
7.Korkmaz S. Mean platelet volume and platelet distribution width levels in patients with mild psoriasis vulgaris with metabolic syndrome. Advances in Dermatology and Allergology/Postȩpy Dermatologii Alergologii, 2018;35:367-71.
8.Gürer MA, Adışen E. Psoriasis, Genel Bilgiler, Epidemiyoloji. Turkderm, 2008;42:15-8.
9.Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2007;298:321-8.
10.Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. Dermatology 2008;216:152-5.
11.Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012;132:556-62,
12.Ataseven A, Temiz SA, Eren G, Özer İ, Dursun R. Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics. Journal of Dermatological Treatment. 2020;31:1-6.
13.Öztürk ZA, Dag MS, Kuyumcu ME, et al. Could platelet indices be new biomarkers for inflammatory bowel diseases. Eur Rev Med Pharmacol Sci 2013;17:334-41.
14.Cakal B, Akoz AG, Ustundag Y, Yalinkilic M, Ulker A, Ankarali H. Red cell distribution width for assessment of activity of inflammatory bowel disease. Dig Dis Sci 2009;54:842-7.
15.Ephrem G. Red blood cell distribution width should indeed be assessed with other inflammatory markers in daily clinical practice. Cardiology 2013;124:61.
16.Balta I, Balta S, Demirkol S, Celik T. Other inflammatory markers and related factors should be kept in mind in metabolic syndrome with psoriasis patients. Arc Dermatol Res 2013;305:459-60.